5.9 S.r.l. is an Italian leading company of weighing systems for medical applications. Monitoring the patient’s weight during invasive medical treatments, allows the health care workers to verify the patient’s health condition just with a glance and simply. Investing in the research has allowed the company to develop an integrated weighing system with touch display that creates a dedicated patient file complete with all the necessary information and storages the patient medical history. 5.9 S.r.l. can develop dedicated and customizable weighing systems in accordance with customer needs, and in addition to its own production line of bed scales and armchair scales, offers a mobile system that can be adapted to multiple devices already in the hospital.
On-site booth: C.200
A Uno Tec Srl
A UNO TEC designs and realizes customized automatic machines for the assembly of medical devices, in plastic materials in clean rooms. Specializing in Infusion Therapy and Dialysis, it constitutes a benchmark in the development of solutions for the assembly of medical products required by the manufacturing medical market. The wide variety of clients, spread across the world, has contributed to enrich its technical knowledge and innovating capability, ensuring an efficient turnkey service.
On-site booth: C.215
Acime Frame is established in 1990 and based in northern France, we design, manufactures and supplies medical equipment for day-care in hospitals and private clinics throughout the world.
Our wide range of innovative products includes treatment chairs for Dialysis Units, Oncology, Haematology, Urology, Gynaecology and Day Surgery. We provide trolleys and stretchers Emergency, Day Surgery and Patient Transfer. We also supply transfer chairs for use throughout hospitals.
Our medical treatment chairs come with a wide range of features including a choice of armrests or side rails.\r\n\r\nWe offer a wide range of options so that our products can be adapted to a wide range of requirements.
The patient’s comfort is much important for us and we’re proud to bring the best service thanks to our manufacture and our upholstery service, a whole team is totally dedicated to the upholstery, many options of different mattress to adapt each product at the client’s request.
Our mastery of the creation process allows us a great flexibility which enables us to provide our customers with a virtually tailor-made service.
On-site booth: B.280
Actualway Medical Devices
We are a Portuguese manufacturer of Therapy Chairs, Sampling, Blood Donation Chairs and Multifunctional Chairs for several medical specialties. We are located in Maia, very close to Porto airport, our name is Via Actual, Lda and our production is branded under Actualway® trade mark.
The company was founded in 2001 and step by step we have been increasing our distribution all over the world thanks to our big efforts in promoting our products. We work to build a long terms relationship with all our partners.
We take this liberty to introduce ourselves to you as one of the leading exporters and manufacturers of Treatment Chairs with reputable quality. We can supply our Chairs within an excellent delivery time, thanks to our efficient management patterns.
The company is rules by 3 owners who all work in the company.We are constantly striving and innovating to improve the quality of life for both the patient and the caregiver. In choosing Actualway® solutions for their needs, our customers are ensuring satisfaction, commitment to excellence and above all a great experience with a accompany that has been founded to care for todays and tomorrow’s needs.
We produce reliable, strong and comfortable products because we do care about the patients and the nurses, and provide an excellent sales service thanks to our flexibility and to our special engineering building patterns. Our company is also ISO9001 + ISO13485 certificated. Actualway® is present in 49 countries worldwide. Our team is made of young, motivated and skilled people to answer to the present and future challenges because the market is more and more demanding. We will keep on improving our chairs and develop our range because this is our duty.
On-site booth: B.260
Aferetica is an innovative SME, founded by managers with thirty years experience in blood purification who wanted to leverage their competence in purification therapies and the know-how in biomedical technologies in order to apply aphaeresis techniques in new fields, such as organ management for transplantation.
Aferetica’s mission is to drive and incentive the creation of a network, which must be able to create, validate and use aphaeresis therapies in clinical practice, initiating their use in new clinical areas.
Aferetica wants to meet current transplantation needs, transforming organ preservation in organ recovering and regeneration, through the combination of Aphaeresis and perfusion techniques.
This mission leads to the design and the development of integrated systems with:
– Dedicated Sorbents.
On-site booth: A.150
Alexion is a global biopharmaceutical company focused on bringing hope to patients and families affected by rare diseases and devastating conditions by delivering innovative, life-changing therapies. Alexion developed and commercializes two complement inhibitors – SOLIRIS® (eculizumab) and ULTOMIRIS® (ravulizumab) – to treat patients with atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), refractory generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). As the global leader in complement inhibition, Alexion is leveraging its experience in complement biology to pursue novel molecules and targets in the complement cascade.
On-site booth: D.210
Alfasigma is one of the top 5 pharmaceutical companies in Italy, with a turnover in 2020 of approximately 1 billion euro. It’s a private company with more than 75% owned by the family of the founder. The Alfasigma legacy is firmly anchored in a long lasting heritage of innovation and success, beginning in 1948 in Bologna (Italy).
From the beginning Alfasigma has always pursued a twofold strategy:
– internally, a strong focus on Research & Development and Manufacturing around some proprietary molecules, some of which represent more than 50% of the sales;
– externally, developing a robust strategy of mergers and acquisitions of other Italian and international companies.
Currently Alfasigma has around 3.000 employees worldwide, 17 direct branches and – through top distributors – its presence spreads over more than 70 countries. In Italy, the company is a leader in the prescription products market where, in addition to the strong focus on Gastroenterology, it is present in many primary care therapeutic areas.
Alfasigma also manufactures and markets over-the-counter products, nutraceuticals and food supplements. Half of the 3000 employees are based in Italy and operating from 5 locations: the headquarters in Bologna, the International Business Unit in Milan and the manufacturing sites located in Pomezia (RM), Alanno (PE) and Sermoneta (LT). Bologna and Pomezia also host Research & Development laboratories. In addition to the Italian locations, Alfasigma has two manufacturing plants in Tortosa, Spain and Shreveport, Louisiana (USA). In addition to the 17 direct branches of Alfasigma, the Company’s presence in the rest of the world is guaranteed by top-level local and international distributors. Alfasigma’s focus remains on the patients, thus it is strongly committed to manufacturing and marketing innovative solutions for a better health and a better quality of life for patients, caregivers and healthcare providers.
Alfasigma L-carnitine is the outcome of 40 years of research by Alfasigma on the role played by carnitine in cellular metabolism. Alfasigma L-carnitine was used in more than 1200 clinical trials, in which our product was administered to thousands of people in absolute safety. Alfasigma L-carnitine is manufactured through patented chemical processes that guarantee the highest levels of efficacy, safety and quality, as proven by the great number of international certifications earned.
On-site booth: D.720
Allmed is a vertically integrated global manufacturer, selling and operating in over 40 countries around the world.
Allmed has a wide product range in the haemodialysis consumables market space, and is home to multiple patented and innovative products, including:
– The market’s only steam-autoclaved Polysulfone dialyzer range
– A special therapy BIOREMA® 26H high-capacity filtration product line, as well as
– The BIOCARB-G: a bicarbonate cartridge whose patented design allows it to enjoy the lowest carbon footprint of any comparable product on the market.
We are committed to offering customised solutions to Haemodialysis professionals and patients in.
On-site booth: A.310
Alnylam is leading the translation of RNA interference (RNAi) into a whole class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA. For more information visit www.alnylam.com.
On-site booth: D.275
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge medicines for rare metabolic diseases.
On-site booth: B.160
Asahi Kasei Medical Europe
In Asahi Kasei’s medical enterprises, we have developed new medical devices and therapeutic technologies and made advances in biopharmaceutical and plasma derivative process engineering. We have achieved these through a high-level synergy of filtration and separation technologies using membranes, filters and adsorbents, together with wide-ranging knowledge and technological expertise in science, mechanical engineering and medical fields. Our filtration and separation technologies for blood and body fluids hold great promise as core technologies for integrative innovation.
On-site booth: D.100
Astellas Pharma Inc
At Astellas Pharma Inc., Changing Tomorrow™ is the ethos that guides everything we do.
We combine innovative science and the latest technology, with our expertise and passion to make a difference, delivering treatments and solutions that improve the lives of patients.
Our Focus Area approach to research concentrates efforts on disease areas where the need is great, but effective treatments are lacking.We are dedicated to addressing unmet medical needs and driving medical solutions in nephrology that deliver value and relief to patients, their families, and carers.
Anaemia is a common and early complication of chronic kidney disease (CKD) affecting approximately one in five people with this condition.¹ It can be associated with increased risk of hospitalisation, mortality, cardiovascular complications, and worsening kidney function.², ³ The condition can also have a significant impact on patients’ quality of life, affecting mobility, self-care, and day-to-day living.² We work alongside healthcare professionals, patients and patient groups to drive initiatives that improve awareness, education, access to treatments and ultimately standards of care for people living with anaemia of CKD. The Astellas Patient Centricity division works to bring the patient’s voice into the organisation to help us understand and address what truly matters to patients. We believe that having a conscious awareness of the patient in all activities, from every area of the company every day, ensures we make the greatest positive impact possible on patients throughout their healthcare journey. For more information, visit our website at www.astellas.com.eu
1. Dmitrieva O, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol 2013; 14: 24. 2013/01/29. DOI: 10.1186/1471-2369-14-24.
2.Eriksson D, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016; 17: 97. 2016/07/28. DOI: 10.1186/s12882-016-0312-9.
3.Schmidt RJ and Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007; 1: 14. 2007/10/04. DOI: 10.1186/1750-4732-1-14. Job code: NEPH_2022_0001_UK Date of preparation: January 2022
On-site booth: D.360
Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca’s three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling comorbidities. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.
On-site booth: D.500
B. Braun Avitum AG
A family-owned company founded in 1839 in Melsungen, Germany, B. Braun today is one of the world’s leading healthcare companies with more than 63,000 employees working in 64 countries. The product range includes dialysis machines and dialysis consumables for chronic dialysis and acute blood purification. In addition to its role as a manufacturer of dialysis equipment, B. Braun is also an important provider of dialysis treatment. B. Braun operates more than 350 renal care centers. Additional care services such as holiday dialysis and pre-dialysis programs are offered in most markets, and B. Braun Avitum cooperates fully with local transplant organizations in different countries.
On-site booth: A.230
Bain Medical Equipment(Guangzhou)Co.,Ltd.
Bain Medial, the professional manufacturer of hemodialysis consumables. 24 years of experience in the industry, with products sell all over the world. Our product portfolio include Dialyzer, Bloodline, AVF Needle, Catheter, Hemodialysis Bicarbonate, Disposable Hemodialysis Care Kits and Dialysis Machine.
On-site booth: A.440
Every day, millions of patients, caregivers and providers around the world rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products and solutions. For 90 years, we’ve been making an impact at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, therapies and digital health solutions available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. We welcome Hillrom to Baxter, where we are uniting to advance patient care worldwide. We’re building on the strengths of two historically innovative and socially responsible companies that will better serve our patients, customers and communities.
To learn more, visit www.baxter.com and follow us on Twitter and LinkedIn.
On-site booth: A.240
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com
On-site booth: A.400
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. At BioCryst, we are passionate about advancing novel therapeutics for patients with rare and serious diseases. BioCryst’s US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama. With expertise in drug discovery, clinical development, and regulatory affairs, we are advancing clinical programs and generating new compounds from our own discovery engine. We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives.
On-site booth: D.150
Bio Preventive Medicine Corp.
Bio Preventive Medicine (BPM) is a leading company in renal biomarker area. As an innovative and clinical staged biotech company, BPM focuses on translating validated and IP-protected biomarkers into diagnostic solutions for unmet clinical needs, especially among the fields of disease’s early detection and prevention in diabetes related complications, such as Diabetic Kidney Disease (DKD), Cardiovascular Disease (CVD), kidney injury, and oncology (upper GI cancer). To advance precision medicine and reduce healthcare burden globally in chronic diseases and oncology, BPM develops clinically proven biomarkers and high value-added diagnostic products, that enable unprecedented efficiencies in the development of therapies. BPM’s expertise in Diabetic Kidney Disease (DKD) and non-proteinuric renal disease led to the development of first breakthrough IVD product, DNlite-IVD103, which detecting a post translational modification of a DKD biomarker and identified by large urinary proteomic studies. DNlite-IVD103 is a non-invasive urinary ELISA test for predicting/ monitoring the progression of DKD, and has obtained CE IVD mark, Malaysia MDA and other regulatory-approvals for global market. BPM constantly contribute its expertise and is seeking to partner and collaborate with leading industry organizations. For more information, please refer to BPM official website: http://www.bpmbiotech.com/
On-site booth: C.220
Bionic Medizintechnik GmbH
With a product range covering products for the vascular access, such as a variety of more than 100 types of fistula needles and numerous accessories for connection and disconnection, as well as high class therapy chairs, Bionic Medizintechnik GmbH is one of the key players in the dialysis field, located near Frankfurt/Main in the heart of Germany. We sell our products worldwide and are market leaders in Europe, setting high standards in quality and puncture characteristics.
On-site booth: D.600
Bioteque Corporation provides solutions in many critical applications such as nephrology and dialysis, cardiovascular catheters, endourology, interventional radiology. With years of effort, we have satisfied medical accreditation including ISO 9001, EN46001, European CE mark, GMP and American FDA 510(K) and also obtain acknowledgement from leading international pharmaceutical corporations. We are supplying quality products include: Pigtail Drainage Catheter / Double Pigtail Ureteral Stent / PCN kits for Nephrostomy, Hemodialysis Bloodline / AV Fistula Needles, IV Infusion Bags, Double Lumen Dialysis Catheter, CVC catheter, CAPD solution system. Our facility is ISO13485, CE-0434 accredited and passed FDA establishment audit. For more information, please visit our website www.bioteq.com.tw
On-site booth: D.280
Since 1990, Bodystat® has specialised in bio-impedance technology, spectroscopy and Cole Modelling. Bodystat® is dedicated to researching bioelectrical impedance technology to provide the innovative electronics that accurately measure body composition and hydration within the human body, non-invasively.
Bodystat’s single, dual and multi-frequency non-invasive devices offer a quick, easy and reliable method of measuring body composition, hydration and nutritional status and cellular health. The Bodystat® range of products includes measurements at critical frequencies to determine intra- and extra-cellular fluid levels, Body Cell Mass and more.
Bodystat® has recently launched their latest generation MultiScan 5000 spectroscopy device. The MultiScan 5000 uses the latest in Cole Modelling to display the volume of over-hydration. The Multiscan 5000 measures the Volume of Fluid Overload, as well as showing Body Composition, Hydration and BIVA Vector graph immediately on the colour touch screen. Raw data, Resistance, Reactance and Phase Angle are calculated at 50 frequencies up to 1000 kHz to help assess Dry Weight and to help assess nutritional status pre and post dialysis.
The MultiScan includes many new features such as elimination of stray capacitance ensuring precise accurate and reproducible measurements, precise Impedance and Phase Angle values at multiple frequencies, new low capacitance leadwires, remote access for updates and system diagnosis and wireless charging providing convenience and safety.
The MultiScan 5000 also displays the Phase Angle and Prediction MarkerTM which is directly measured without the need for weight, gender, age and population group.
Phase Angle is an excellent indicator of cell membrane health based on the distribution of water inside and outside of the cells. Tracking the changes in Phase Angle is an effective indicator for monitoring the change in health and muscle mass since Phase Angle measures at the cellular level. Low Phase Angle is associated with malnutrition and nutrition risk.
The Prediction MarkerTM is the ratio between Extracellular Water and Total Body Water. The Prediction MarkerTM measures the movement of fluids in and out of the cells based on the Impedance ratio. The Prediction MarkerTM uses the latest in Cole Modelling providing accurate tissue model parameters and allowing for the tracking of changes in ECW/TBW which is crucial for dialysis patients. The Prediction MarkerTM is particularly useful in Critical Care and ICU settings were fluids needs to be measured constantly.
The MultiScan can be used in a number of clinical settings such Renal Dialysis, Kidney Disease, Covid including Long Covid, Cachexia, Sarcopenia, Lymphoedema and Critical Care.
For further information, contact Bodystat® at firstname.lastname@example.org
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an Alliance that centers on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the Alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need. Clinical trials have been initiated to evaluate the impact of empagliflozin on people living with heart failure or CKD.
On-site booth: A.320
Commerical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
On-site booth: C.110
Chiesi Farmaceutici S.p.A.
After 85 years of experience, Chiesi Group, a family-owned and -run certified B Corporation company, launched Chiesi Global Rare Diseases in 2020. Chiesi Global Rare Diseases is focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. Chiesi is the largest pharmaceutical group in the world to be awarded B Corp Certification. B Corps are businesses that balance purpose with profit. They are legally required to consider the impact of their decisions on their workers, customers, suppliers, community, and the environment. This is a global movement of people using business as a force for good.
On-site booth: D.120
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
On-site booth: D.320
Cibiltech is a pioneer in the development of artificial intelligence-based software medical devices, offering its solutions to patients, healthcare professionals and to the pharmaceutical industry. Cibiltech’s ambition is to build the distribution platform for algorithms to prevent organ failures. Cibiltech’s expertise in the regulatory, clinical and infrastructure aspects of digital health solutions places it in a unique position to achieve this goal.
On-site booth: D.740
As a professional congress organizer (PCO), we have a modular approach in providing congress management services, regardless of size or location. Over the last 15 years, Conventus Credo handled over 300 projects for institutions, academic and medical sectors, organizations and companies. Whether they are looking for a partial support or complete congress logistics, we tailor our serviced to match our clients’ needs.
Our PCO services include: congress planning, budgeting and financial management, marketing and communications strategies, venue selection, hotel reservation/accommodation, sponsors and exhibits, speakers management, delegate services, conference materials and print, social program, tours and transport, congress technology, on-site management, general management
On-site booth: D.140
Since 1936 Culligan manufactures a complete line of units and accessories for all water treatments, and has an extensive licensee distribution network in Italy and all over the world, granting efficient and timely service. With over 30 years specific experience in the treatment water for dialysis Culligan has developed innovative system that are displayed at Culligan booth.
On-site booth: D.310
CytoSorbents Europe GmbH
CytoSorbents is a critical care focused immunotherapy company using blood purification to modulate systemic inflammation – with the goal of preventing or treating multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. To date, more than 162,000 individual applications have been performed in more than 800 clinical settings worldwide.
On-site booth: A.160
Based in Switzerland, Dialife is a global provider of high quality products, equipment and services for renal care. We offer a comprehensive range of devices and products for hemodialysis treatment, including dialysis machines, dialyzers, tubing sets, fistula needles, sodium bicarbonate cartridges, concentrates, disinfectants, endotoxin filters, on/off kits and more. We also provide turnkey solutions to set up hemodialysis centers, as well as transfer technology for the production of dialysis products.
On-site booth: C.120
FLAVIS is a line of kidney-friendly medical foods designed for those with Chronic Kidney Disease (CKD). The brand is the result of Dr. Schär’s experience and dedication to research in the field of Medical Foods for Specific Nutritional Needs for over 30 years. For CKD, the clearly defined form of nutrition is called renal diet, with a reduced intake of protein and minerals such as sodium, potassium and phosphorus. A protein restriction with sufficient energy supply is effective in stabilizing residual kidney function and delaying the need to initiate a renal replacement therapy. With the product range of kidney-friendly medical foods, FLAVIS supports the positive effects of a special nutritional therapy for chronic kidney disease. The low protein FLAVIS products have a balanced composition of minerals (sodium, phosphorus, potassium) and are rich in energy and fibers. Flavis medical foods help patients meeting their nutritional needs. They support maintaining good nutritional status and facilitate adhering to medical nutrition therapy, which controls signs and symptoms of CKD and slows down disease progression. FLAVIS for a better quality of life.
On-site booth: A.120
Dustri-Verlag Dr. Karl Feistle / Clinical Nephrology
Dustri-Verlag was founded in the late 40s of the last century. In 1965, the founder Karl Müller, a printer from Remscheid, Germany, sold Dustri-Verlag to Dr. Karl Feistle, an ambitious young publisher. In 1999, Dustri-Verlag was taken over by Karl’s sons Frank and Joerg Feistle, who have further expanded their father’s success. In 2003, the American office of Dustri-Verlag was founded in Rockledge, FL, in order to improve contacts to its authors and readers.
For the past 50 years, Dustri-Verlag has been specializing in medical literature. The publisher’s oldest periodical was the Medical Literature Adviser (MLA), offering information on the latest medical books to booksellers. The publication of medical books, such as Facies dolorosa by Hans Kilian a famous German surgeon, also started soon. First published in 1971, Nieren- und Hochdruckkrankheiten (Renal and Hypertensive Diseases, founding editor R. Kluthe) was Dustri-\Verlag’s first journal. In 1973, the first English language journal followed: Clinical Nephrology (founding editor R. Kluthe), soon well known as the “green journal”, was one of the first in its field. Since 1975, six new German-language journals have been added to the program: Allergologie (Allergy), Atemwegs- und Lungenkrankenheiten (Airway and Lung Diseases), Intensiv- und Notfallbehandlung (Critical Care), Verdauungskrankeiten (Gastroenterology), Prävention und Rehabilitation (Prevention and Rehabilitation), and Dermatologie in Beruf und Umwelt (Occupational and Environmental Dermatology). In addition to Clinical Nephrology, Dustri-Verlag also publishes three other international English-language journals: Clinical Neuropathology, International Journal of Clinical Pharmacology and Therapeutics, and Trace Elements and Electrolytes.
A book program was launched in the 1970s, when the first yellow pocket books were published. Today, Dustri-Verlag has a broad spectrum of books for many special fields of medicine – from large standard works to highly specialized textbooks and useful patient guides.
Since 1990, Dustri-Verlag has been typesetting in its own studio. This has speeded up production and opened new technical possibilities. Dustri-Verlag has also tackled the challenges of digital revolution. All journal contents as well as the most important book contents are offered online in electronic form. Many important libraries worldwide are connected to the Dustri database. Furthermore, Dustri-Verlag has developed its own online submission system for a professional review process. Dustri-Verlag particularly aims at supporting young doctors in publishing their research in journal articles or books, ensuring that the content reaches a worldwide audience – on request also as open access article. Everybody at Dustri-Verlag works with great personal commitment to satisfy our authors and readers.
On-site booth: D.420
DWA GmbH & Co. KG
Since 1984, DWA has specialized in innovative solutions for the supply of high purity water to dialysis centers – worldwide. DWA develops systems for the production of ultrapure permeate and its distribution right to the dialysis machine. Our expertise in water treatment covers all aspects from the pre-treatment stages, through reverse osmosis, ultrafiltration and heat-disinfection systems, right up to the supply connection through to the dialysis machine. In addition, DWA offers systems for the distribution of acid and bicarbonate concentrates. Since its inception, DWA has been setting standards in dialysis water treatment and is the only company producing ultra-clean permeate by the combination of reverse osmosis and central ultrafiltration, including integrated simultaneous heat-disinfection of the ring mains to the dialysis machines. DWA is your global partner for the design, planning, installation, extension or conversion of dialysis centers and offers project management, installation and commissioning as well as service and maintenance from a single dedicated source.
On-site booth: A.420
We have been producing single use sets for more than 40 years. Focused on the Haemodialysis market, producing bloodlines and accessories, in the last years we have implemented our range adding oncology, infusion and transfusion sets. Our company structure, always evolving, allows us to promptly react to the increasing requirements of the market. Our customers have confidence in us as a reliable partner with a track record of long-lasting cooperation. On time delivery and service are our standard.
On-site booth: A.170
Emodial develops advanced solutions for the vascular access management in hemodialysis, oncology, intensive care and parenteral nutrition: the Silver line of pads, plasters and pockets for CVCs, peritoneal catheters and PICCs releasing silver ions with antibacterial and anti-inflammatory action, also available in procedural kits for start/end treatment and, upon completion of advanced dressings, the innovative waterproof pockets for catheter, for bath and shower. Since its foundation, Emodial has been committed to develop what we can call the “therapeutical alliance”, a model based on the direct cooperation between the main actors of the vascular access scenario: doctors, nurses, patients, patients associations, caregivers. Starting from the direct experience of patients, which Emodial collects through dialogue with them and with patient associations, the aim is to create solutions to accomplish its mission and also its promise: improve the patient’s quality of life, raise healthcare standards, contain and optimize healthcare spending and reduce healthcare time and risks associated with it.
On-site booth: D.200
European Society for Paediatric Nephrology
The aim of the Society is to promote research knowledge of paediatric nephrology through teaching, scientific meetings and other methods, for the benefit of children with renal disease.
Founded in 1967, the European Society for Paediatric Nephrology or ESPN, is the professional association for those researching or delivering care for children with kidney disease within Europe. We include the geographical definition of Europe and are not limited by the European Union though we link with some of the EU initiatives, such as ERKNet.
An annual meeting of the ESPN takes place every autumn. Currently, every 3 years this is combined with the tri-annual meeting of the International Pediatric Nephrology Association. The officers of the ESPN are the President and Assistant President who serve a 3-year term, extendable for a further 2 years, a treasurer and a council who are elected every 3 years.
FARMASOL is one of the successful players in hemodialysis market globally. It supports medical care all over world with a whole wide range of hemodialysis products and services. Since 2005, FARMASOL has continually evolved to advance high quality products in hemodialysis treatment, providing high quality and cost effective solutions to help people lead healthier lives. Our mission is to create better living conditions for our more than 500 patients under its roof as well as the patients all over the world by cooperating with doctors, employers and patients, bringing higher quality, safe and cost effective products. In order to have more detailed information regarding our current and new products please visit our booth B270!
On-site booth: B.270
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies. With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.
On-site booth: D.300
Fresenius Medical Care
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care.
With more than 40 years of presence on the market, the Gardhen bilance family owned business is growing year by year with new projects, new products and new relationship with distributors. Our plant is located in Italy, thence our production is totally MADE in ITALY. Italian talents for a marvellous Team. Ready to a continuous innovation. We are able to provide tailor made solutions for every needs that comes out from customers Our commitment for the dialysis is providing comfortable accommodation for the patients and easy to use solutions for the medical staff. Durable solutions to provide beds and chairs with or without integrated scale for the continuous monitoring of the patient weight. It begins with R&D than it goes through Quality Management and Manufacturing. The process comes to an end with a final quality Testing. This is the result of a 40 years of history.
On-site booth: C.420
The Swiss family owned company Geistlich Pharma develops and produces pharmaceutical and medical devices since 1851. A worldwide distribution network provides valuable assistance in solving medical issues. Products such as the antimicrobial catheter lock solution Geistlich TauroSept® for the prevention and treatment of CRBSIs originate from the company’s own research facilities in Central Switzerland.
On-site booth: D.220
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 400 people managing 38 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials.
GSK is a global healthcare company with a special interest in nephrology and a commitment to the community impacted by renal disease. We are proud to be joining experts from around the world to discuss our science, create opportunities to connect with peers, and deliver compelling content at this year’s ERA Congress. As we are committed to education in nephrology, we welcome the opportunity to connect around our science. Join us for our two scientific industry symposia, both live on-site and streamed virtually:
Moving forward in anaemia of CKD: what are you doing?
Will be presented Friday, 20 May, 09:45 – 10:45 CEST
Room N02 on-site in Paris
Lupus nephritis: can we preserve kidney function? Current challenges and practical considerations
Will be presented Friday, 20 May, 13:30 – 14:30 CEST
Room N01 on-site in Paris
Additionally, we are excited to connect again in person! Please come meet with us at our exhibition booth #A.300.
Lastly, keep an eye out for our presence in the Congress bulletins, newsletters, and digital atrium screens on-site.
We look forward to connecting with you virtually or seeing you in Paris!
The materials for GSK contained in this virtual exhibition are approved for use only in France. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).
On-site booth: A.300
GREINER GMBH – WE DESIGN QUALITY GREINER GmbH is a german family-owned company and one of the leading producers of seats and chairs for specific application areas. From styling chairs and shampoo chairs to ergonomical car seats up to medical couches and chairs, GREINER GmbH provides high quality interior for professional application areas. The focus is on the equipment of hospitals, medical practices, hairdressers shops and vehicles. The basis for this success is a balanced core and business value, based on quality, competence, design, partnership and sustainability.
On-site booth: A.420
Hansa Biopharma is a pioneering biopharmaceutical company and our mission is to develop innovative, lifesaving, and life-changing treatments for patients with rare immunological conditions. Hansa has developed a first-in-class Immunoglobulin-G (IgG) antibody cleaving enzyme therapy, which can enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program exploring a broad range of conditions. Our pipeline is focused on advancing the Company’s proprietary enzyme technology to develop the next generation of IgG-cleaving enzymes to enable repeat dosing in relapsing autoimmune diseases, chronic transplant rejection, oncology, and gene therapy.
On-site booth: D.240
Herco Wassertechnik GmbH
Herco Wassertechnik GmbH develops and offers complete water treatment solutions for dialysis applications since 1980.
Our products are water softeners and filters for pre-treatment as well as reverse osmosis, ring main, media supply panels and concentrate mixing systems that meet the MDD/MDR requirements under the quality certificate EN ISO 13485.
Herco is an experienced manufacturer for water treatment equipment for medical, pharmaceutical and any kind of industrial applications as well as for CSSD.
With our own design & development department we are able to provide standardized products as well as customized solutions to meet your needs.
On-site booth: B.150
ICU Medical, Inc.
ICU Medical offers IV therapy products to help meet your infusion therapy needs. The ClearGuard™ HD antimicrobial barrier cap is the first and only device that kills infection-causing bacteria inside a hemodialysis catheter hub. The cap is simple to use, yet highly effective and clinically proven to reduce the incidence of central line-associated bloodstream infections (CLABSIs) in hemodialysis catheter patients. Learn more at www.icumed.com
On-site booth: D.185
Imuna Pharm, a.s.
IMUNA PHARM, a.s. is a pharmaceutical company based in Slovak Republic with over 60 years of experience in manufacturing of drugs, medical devices and veterinary products. With its most modern manufacturing facility built in 2016 is able to produce single & multi-chamber bags with volume from 50 ml up to 5 000 ml. Has its own branded products while offers contract manufacturing services for other multinational companies as well. Our portfolio ranging from infusion solutions, irrigation solutions, dialysis solutions and concentrates, anticoagulant solutions, Carbo products, and many other products we are happy to present you. Currently supplies its products in many countries across Europe, Asia, Middle-East, Africa and is in process of market launch in U.S. territories. IMUNA® WHERE INOVATIONS MEET TRADITIONS
On-site booth: D.750
InBody is our own brand of body composition analyzer that can be met in hospitals and other variety of fields. In 1996, we introduced “InBody” with advanced technology that guarantees accuracy and reproducibility in the era when there was no technology of accurate body composition analysis and established itself as the most practical and accurate body composition analyzer.In the last 25 years, body composition analysis has established itself as a standard practice in various fields and InBody has continuously strived to further expand its application to specialized areas, such as dialysis, rehabilitation, nutrition, and etc. With the need for the precise measurement of body water, InBody introduces a new standard for body water analysis, BWA 2.0. The BWA 2.0 is equipped with state-of-the-art 3MHz technology and provides extensive research parameters for professionals to better suit diverse patients with different conditions and medical specialties than ever before. Find out more info about A New Standard for Body Water Analysis at our stand, C.140.
On-site booth: C.140
Infomed, worldwide player on blood purification devices offers complete solutions for chronic and acute renal replacement (homecare and hospital environment) and for plasma therapies. Active since 25 years, Infomed continuously innovates to create devices designed to reach your topmost needs. Dimi, our homecare dialysis device, is the partner for a new life at home. Dimi was thought to offer the freedom to provide the optimal treatment conditions fulfilling the patient requirements. Our products are adapted for adult, child and babies. We work for human well-being thanks to a large range of treatments available on our devices which include the “all in one” philosophy, as Infomed, we focus on you!
On-site booth: A.210
ISPD International Society for Peritoneal Dialysis
The International Society for Peritoneal Dialysis works to increase the global uptake, promote quality practice, and achieve optimal outcomes of peritoneal dialysis through enhanced advocacy, research, and education, in order to improve the health and well-being of people living with end-stage kidney disease or suffering from acute kidney injury.
We invite you to visit our website www.ispd.org and find everything about our activities and programs:
a) our upcoming ISPD 2022 Congress in Singapore 11-14 August www.ispd2022.com
b) our renowned ISPD Guidelines and many other educational materials for doctors and nurses (courses, webinars, lecture series, etc)
c) our ISPD Fellowship grants and our support program for research projects on PD
d) our committees and chapters and all their activities.
e) our scientific journal PD Internatiional (PDI)
On-site booth: D.450
International Society of Nephrology
The International Society of Nephrology (ISN) is a global professional association dedicated to advancing kidney health worldwide since 1960 through education, grants, research, and advocacy. Through its members and global network of national and regional societies, the ISN engages 30,000 health professionals from across the globe to reduce the burden of kidney diseases and provide optimal health care for patients. Join the ISN’s global community via our social media networks on Twitter (@ISNKidneyCare), Instagram, LinkedIn and Facebook. Learn more about the ISN, its global professional network and extensive membership benefits at www.theisn.org.
On-site booth: D.400
Established in 1989, Jafron Biomedical (ChiNext: JFSW) is a global provider of technology, product and therapy service in the hemoadsorption industry.
On-site booth: C.100
Joline GmbH & Co. KG
Joline is an internationally active medical device company located in the South of Germany with more than 15 years experience in minimally invasive therapies. Joline is an expert provider of catheter, balloon and stent technology for various medical applications and maintains an important tradition of “Made in Germany” quality in all its products and services. All Joline products are developed and produced exclusively in Germany. We integrate quality aspects in our daily work and strive to meet the high standards of our customers. The highest priority we place on the health and safety of our patients.
On-site booths: H.7.3 and D.260
Journal of Kidney Care
Journal of Kidney Care Journal of Kidney Care (JKC) is the essential bi‑monthly double-blind peer‑reviewed publication for all members of the multidisciplinary renal team. It covers several clinical areas of renal medicine, such as dialysis, transplantation, diabetes, anaemia, pharmacy and nutrition. Every issue of the journal will have a clinical focus on one of these key aspects of kidney care.
Founded 131 years ago, Karger Publishers is a worldwide publisher of scientific and medical content based in Switzerland. A comprehensive range of topics covered by leading experts characterizes our nephrology program ranging from the book series Contributions to Nephrology and print journals such as Nephron, American Journal of Nephrology, Blood Purification, as well as open-access journals including Kidney and Blood Pressure Research, Cardiorenal Medicine, Kidney Diseases, Glomerular Diseases, and Case Reports in Nephrology and Dialysis. In addition, the Nephrology Viewpoints blog offers up-to-date assessments of latest Karger Nephrology articles.
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the patients it serves.
On-site booth: D.700
Design and quality by LiKAMED
LiKAMED is a globally leading manufacturer of therapy chairs. Our products combine quality, patient comfort, longevity and cost efficiency with design and more than 40 years of experience. In addition to a wide range of products, we also offer service and technical expertise to cover every needs of our customers all over the world.
On-site booth: B.110
This year Medcomp returns in-person to ERA showcasing our wide range of hemodialysis products! Did you know that Medcomp® develops, manufactures, markets, and supports cutting-edge vascular access devices and accessories to meet the clinical needs of the medical industry, particularly in the fields of interventional medicine and dialysis? Our company’s engineering and applications expertise provides superior products whose progressive designs accommodate advances in medicine and whose quality anticipates the requirements of our professional clients and the patients they serve. Stop by our booth to see in-person what products we have to offer!
On-site booth: A.180
MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on delivering actionable organ function measurements. In preclinical research the Transdermal Mini GFR Monitor system tracks Glomerular Filtration Rate (GFR) without restraining the animal. The system obviates the need for blood sampling, urine collection, and laboratory assays thus enabling superior trial design. The result is enhanced kidney therapeutic assessment, nephrotoxicity evaluation and fundamental understanding of kidney function in animals.
On-site booth: D.190
Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company’s core business. R&D focus has been integrated over the years with a broad offer of sterile single use products manufactured in two facilities with a highly automated production systems. In addition to the portfolio of disposable medical device and electromedical equipment, Medica Group, through the subsidiary Tecnoideal, offers a wide range of machines for medical disposable’s production, with increasing level of automation. Hollow fiber spinning for hemofiltration, plasmapheresis and water ultrafiltration represents the core technology of the company. In recent years, the drive to find new products and markets has led the Group to launch the Medica Water Division, for the development and commercialization of microbial water filtration devices and to develop products for new markets as bio-regenerative medicine and organ transplantation.
On-site booth: A.100
MEDIKIT is a leading Japanese manufacturer of medical devices for vascular access such as plastic fistula cannula and intravenous catheter along with interventional instruments. We support hospitals and healthcare services around the world as a strong and reliable technology and service partner. MEDIKIT develops innovative products with a high commitment to quality, and thus intends to contribute to the improvement of treatments and future medical technologies. Our mission is to reduce the burden on patients during the treatment and at the same time improve safety for medical staff. In this way, we want to be of help to the well-being of the societies in which we live.
On-site booth: B.140
Bold thinking. Bolder actions. We are Medtronic. We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.
On-site booth: C.160
MedXL Europe BV
MedXL Europe BV is a Dutch based medical device company with a key focus on the area of Vascular Access and automated systems for the prepration of medication in syringes. Providing market leading solutions for both central venous catheter and AV fistula access. We are committed to helping patients and healthcare professionals to maintain vascular access patency whilst simultaneously reducing catheter related blood stream infections (CRBSI). Our team of experts have extensive experience of providing catheter care and offering solutions for a wide array of access issues in Europe, South, Middle & North-America, Middle-East and Africa. www.medxl-europe.com
On-site booth: C.205
NephroCan is a Canadian company committed to improving the quality of life for patients with End Stage Renal Disease (ESRD). As a trusted partner in the field, we offer the A to Z of hemodialysis consumables, equipment and machinery with the goal to be a singular resource for full package dialysis treatments. With a patient-focused philosophy, we believe global dialysis care should be versatile, equal and accessible, and, therefore, our product range caters to every need.
On-site booth: B.130
Most innovative company in the field of dialysis vascular access devices revolutionary devices patented by Nephrokit: particularly to reduce time to clot on fistula puncture sites in 3 minutes with Mozaik and Iris and minimoz devices securement of needle fistula with papyrus device and Solukat to protect central catheter ends and exit sites
On-site booth: c.410
NIKKISO, a pioneer in Renal Replacement Therapies, strives to advance complex medical technologies that optimise patient care in End-stage Renal and Critical Care areas. Through our commitment to improving clinical efficiency and patient QoL, Nikkiso has built a global reputation for unparalleled quality and innovation. This is mirrored by technical and medical solutions integrated in NIKKISO’s medical and health care devices.
Aeroclear, our novel air disinfection device, integrates UV-C LED with the world’s highest performance, developed with the Novel Prize winner Prof. Hiroshi Amano. Aeroclear decontaminates areas of aerosol-borne viruses and bacteria. This with extremely low energy consumption and without any additional costs for disposables (e.g. HEPA filter).
DBB-EXA series, our dialysis machines for online hemodialysis (online HD) and online hemodiafiltration (online HDF), provide high-end usability and a wide range of value-oriented solutions and features, achieved by integrating decades of NIKKISO’s expertise in Renal Replacement Therapies. DBB-EXA ES is today the first launched single pump dialysis machine that performs online priming, online bolus and online wash back in HD treatments. The integrated automatisms of the DBB-EXA (e.g. automatic priming, treatment start and wash back), and its proven reliability, contribute to the noticeable success of the DBB-EXA in Western Europe countries, underlined by growing market shares and customers satisfaction. PureADJUST, our compact hemoperfusion pump, offers a broad touch-screen for a clear visibility, a smart layout to favor easy blood circuit setup and an on-screen navigation to support simple operation. Further, frequently used Direct Hemoperfusion Adsorbers can be pre-registered to enhance versatility.
On-site booth: A.200
Nipro Medical Europe
Nipro Renal Care is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 33.000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries. Nipro Renal Care is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment. In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro Renal Care is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs. BECAUSE EVERY LIFE DESERVES AFFORDABLE CARE
On-site booth: A.410
Nova Biomedical is a world leader in point of care and critical care in vitro diagnostics. We offer products that aid in renal function assessment and can be used either within or outside the hospital setting.
• Stat Profile Prime Plus® blood gas critical care analyser with specialised kidney function tests including tests for iMg, Urea, Creatinine, and estimated Plasma Volume (ePV). Prime Plus uses maintenance-free sensors and offers a comprehensive 22-test blood gas/critical care menu. The full menu includes pH, PCO2, PO2, SO2%, Na, K, Cl, iCa, iMg, Glucose, Lactate, BUN/Urea, Creatinine, Hct, Hb, ePV, MCHC, SO2%, and CO-Oximetry.
• StatSensor® Creatinine measures capillary whole blood creatinine and calculates eGFR to enable a rapid assessment of renal function prior to the administration of nephrotoxic drugs in areas such as Accident & Emergency, Radiology or Oncology. • NovaMax® Pro Creatinine/eGFR is an important new tool to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The Nova Max Pro measures blood creatinine and calculates estimated glomerular filtration rate (eGFR) using the CKD-EPI equation, two important indicators of overall kidney function, from a tiny 1.2 microliter capillary fingerstick blood sample in just 30 seconds.
• Allegro®, a compact, capillary blood analyser offering a kidney function panel designed for use in hospitals, primary care or clinics. The system can measure HbA1c, Lipids, Glucose, Creatinine, CRP and PT/INR from capillary whole blood, plus Urine Albumin and Creatinine; with all tests using disposable cartridges and test strips.
On-site booth: C.130
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
On-site booth: A.220
Novo Nordisk A/S
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic diseases. Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity, chronic kidney disease, cardiovascular disease and NASH. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries.
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class immunology, immuno-oncology and anti-addiction therapeutics.
Omeros’ pipeline is led by its complement franchise of protein and orally available small-molecule drug candidates targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and MASP-3, the key activator of the alternative pathway. These include the clinical assets narsoplimab and the longer-acting OMS1029 – both MASP-2 antibodies – and the MASP-3 antibody OMS906. Narsoplimab has been granted FDA’s Breakthrough Therapy and Orphan designations and EMA’s Orphan designation for immunoglobulin A (IgA) nephropathy and is currently in phase 3 development for this indication. Narsoplimab is not approved nor commercially available in any country globally.
On-site booth: D.130
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.
Our 47,000 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology and haemato-oncology.
On-site booth: D.730
Oxford University Press
Oxford University Press publishes some of the world’s most prestigious and respected books, journals, and online products, including the ERA journals: Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Journal (CKJ).
NDT is the leading nephrology journal in Europe and renowned worldwide, devoted to original clinical and laboratory research in nephrology, dialysis and transplantation. Explore the journal: https://academic.oup.com/ndt CKJ is a fully Open Access journal providing essential educational and training resources integrating clinical, translational and educational research into clinical practice.
Explore the journal: https://academic.oup.com/ckj
Palladio Biosciences, Inc, a Centessa Company
Palladio Biosciences, Inc., a subsidiary of Centessa Pharmaceuticals plc, is actively investigating the potential of its product candidate, lixivaptan, in subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Lixivaptan is an investigational, oral, nonpeptide selective vasopressin V2 receptor antagonist. Dosing of subjects in the pivotal Phase 3 clinical trial (ACTION study) has commenced. The trial is expected to enroll approximately 1,350 subjects across more than 200 sites in over 20 countries. The scientific purpose of the trial is to demonstrate that lixivaptan could slow the decline in renal function that is typically observed in ADPKD patients.
On-site booth: D.315
Leader in home hemodialysis, Physidia is a French company specialized in developing, manufacturing and commercializing an innovative equipment and disposables for delivering frequent home hemodialysis treatment.
Physidia’s innovations are based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a performing treatment in total autonomy.
Created by an expert team, Physidia’s S³ monitor has been specifically developed to respond to the needs of simplicity and safety of ESRD patients in home hemodialysis. The Physidia’s S³ offers the treatment of renal failure with daily dialysis sessions of 2 to 3 hours 5 to 6 times a week. Daily hemodialysis is recognized today as the most physiological therapy for the patient experiencing renal failure as this therapy provides outcomes close to natural kidney functioning.
Physidia is present today in 14 countries, operating directly in France and The United Kingdom and through distributor partners in the rest of Europe. Since its origin, the principal ethos of the company has been innovation with exceptional service by providing comfort, freedom and security to every patient.
On-site booth: A.130
Quanta Dialysis Technologies
Quanta Dialysis Technologies is making dialysis more accessible to every patient in every setting with its SC+ hemodialysis system. SC+ is an end-to-end solution with performance comparable to a large traditional machine, and all the flexibility you need to deliver hemodialysis across the continuum of care. With its compact size, intuitive design and user interface, and proven performance, SC+ offers a portable solution that delivers operational efficiencies with powerful clinical outcomes. SC+ is commercially available in the United Kingdom for home and hospital use and is FDA-cleared for use in chronic and acute care settings.
Follow us on LinkedIn, Twitter, and Facebook for updates and more.
On-site booth: D.710
Our scientific mission is to identify, develop, and commercialize small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the cellular response to injury.
On-site booth: C.400
Redsense Medical A
Redsense Medical is a Swedish medical technology company with operations mainly in Europe and the United States. The company has developed the Redsense Alarm system, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood loss. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
On-site booth: C.430
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transforming the care for patients living with rare genetic diseases of obesity. Our science is dedicated to the understanding of rare genetic diseases of obesity caused by an impaired pathway in the brain known as the melanocortin-4 receptor (MC4R) pathway. For more information about the science and our solutions, please visit our website: www.rhythmtx.com
On-site booth: D.305
Rontis is a leading diversified Switzerland Healthcare Company with a long history and proven track record in R&D, manufacturing, and distribution of, Medical Devices, Pharmaceuticals, Nutrition and Dermaceutical products as well as in the provision of Dialysis Services. Our philosophy is to specialize in different therapeutic areas by offering innovative solutions and support our customer’s needs. Medical Devices Division: The Medical Devices division is committed to the application of non-invasive therapies for Interventional Cardiology & Radiology procedures by applying state-of-the-art technologies in R&D, production, and packaging. We additionally produce disposables for Nephrology (extracorporeal bloodline circuits, which we can manufacture for any available dialysis machine, following your specifications and special features needs), and Liquid Administration products. Pharmaceutical Division: Rontis has a vertically organized manufacturing infrastructure that is supported by the R&D department and is implemented through Standard Operating Procedures. Infant Nutrition Division: Rontis has developed a highly specialized range of standard and special infant and baby nutrition formulas. Dermaceuticals Division: Rontis, also has developed a series of dermaceutical products which are especially designed and studied to deal with the various needs of babies and young children. On top of the manufacturing of products with the “Rontis” brand name, we also provide OEM services along with custom-made solutions and multiple product configurations. Website: www.rontis.com
On-site booth: A.325
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions
On-site booth: B.100
About STADA Arzneimittel
AG STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2021, STADA achieved group sales of EUR 3,249.5 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 776.5 million. As of 31 December 2021, STADA employed 12,520 people worldwide.
On-site booth: C.110
Sterifluids team has the experience on developing and manufacturing hemodialysis concentrations over 30 years. The products are being manufactured under strict 13485 standards and CE granted by BSI as our proud notify body. We assure the quality of our products in our factory located in Lisbon, Portugal. All the hemodialysis formulas and concentrations we manufacture are compatible and widely used around the world, adjusting each variations to each type of patient. In the wide range of sizes we can supply the hemodialysis concentrates we have the following options to cover if it will be used on a single patient or in a distribution system: -\t5L and 11L jerrycans -\t600L and 1000L rigid containers -\t1000L disposable carton containers Please contact us to confirm if we can manufacture your desired formulation, and if we don’t have it, we will develop it for you.
On-site booth: D.630
In 2000, TauroPharm GmbH was founded as a German company specialising in medical devices with antimicrobial, antibiofilm and antiocclusive efficacy.
Based on its innovative products, we aim to develop more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Throughout this process, improving the patient’s quality of life remains our top priority. Since there is an urgent need for our products, especially in light of the steadily increasing number of antibiotics-resistant pathogens, TauroLock is recommended in interdisciplinary national and international guidelines. All products have been investigated in independent scientific studies with excellent study results.
Products: TauroLock™ TauroLock™-Hep100 TauroLock™-Hep500 TauroLock™-U25.000 NutriLock™
On-site booth: D.265
Therakos / Mallinckrodt Pharmaceuticals
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Our Specialty Brands segment includes branded medicines and the Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.
Therakos is a specialty brand of Mallinckrodt that focuses on the delivery of ECP Immunomodulation. The THERAKOS™ CELLEX™ Photopheresis System is the world’s only fully integrated and validated ECP system and is used by over 300 treatment centres in over 30 countries worldwide.
Beyond the THERAKOS™ CELLEX™ Photopheresis System, we offer a comprehensive range of support services to help enable healthcare professionals (HCPs) to deliver optimised ECP immunomodulation to patients.
Therakos have been crafting ECP solutions (products, services and education) since 1987.
To learn more about this product visit www.therakos.eu
On-site booth: D.610
Toray Medical Co., Ltd.
Toray Medical Co., Ltd. is a member company of Toray Group, specializing in healthcare field business. Toray is a leading manufacturer of synthetic fibers and dedicated to the development of dialysis products under its corporate slogan, “Innovation by Chemistry”. Toray supports high quality and advanced medical care with bio-compatible polymethylmethacrylate dialyzer “FILTRYZER”, high flux polysulfone dialyzer “TORAYSULFONE”, “TORAYLIGHT” and dialysis machine.
On-site booth: A.330
At Travere Therapeutics we are in rare for life. We come together every day to help patients, families and caregivers as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop and deliver life-changing therapies. We continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
On-site booth: A.340
Vertex, a global biotechnology company, invests in scientific innovation hoping to create transformative medicines for people with serious diseases. The company has multiple approved medicines that target the underlying cause of cystic fibrosis (CF) and continues to advance its research in CF. Vertex has a broad and deep pipeline, including cell and genetic therapies or small molecule approaches with the aim of targeting serious diseases like APOL1-mediated kidney disease.
On-site booth: B.120
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology.
The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
On-site booths: D.350, D.330 and D.230
Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. We are a worldwide leader in specialized diagnostics in the specialties of Hemostasis, Acute Care Diagnostics and Autoimmunity. At present, we operate directly in nearly 30 countries and in more than 100 territories through distributors. Our R&D and production centers are located in the United States and Europe. Every day, hospitals and laboratories around the world use our reagents and systems to test 1.8 million patient samples.
Glycated Albumin (GA) is an important part of the Werfen Clinical Chemistry portfolio. GA is a mid-term glycaemic marker. It is a unique marker capable to address and evaluate glycaemic status in DKD patients, highlighting therapy adherence and success or changes in glycaemic profiles.
Find out more about our Specialized Diagnostic Solutions in Nephrology and visit us at our booth!
On-site booth: D.620
Wisepress Medical Bookshop
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.